ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

7,165Medicare Part D Prescriptions Filled, Including Refills

Rank: 375 out of 1000

$367K Total Retail Price of All Prescriptions

Rank: 381 out of 1000

247 Patients Receiving at Least One Drug in Part D
90%Patients 65 Years and Older
56% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Alabama
Lower avg

Schedule Two
Controlled Substances

7% of this provider’s 247 patients filled at least one prescription for a schedule two drug, compared to an average of 4%.

Schedule Three
Controlled Substances

24% of this provider’s 247 patients filled at least one prescription for a schedule three drug, compared to an average of 20%.

Risky Drugs to Seniors

1% of this provider’s 6,444 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

21% of this provider’s prescriptions were for brand-name drugs, compared to an average of 21%.

Prescription Price

$51 was the average price of a prescription from this provider, compared to $49 among peers.

Prescriptions per Patient

29 is the average number of prescriptions (including refills) per patient, compared to an average of 21.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Alabama
LEVOTHYROXINE SODIUM 407 398 1 4
POTASSIUM CHLORIDE 256 224 2 10
AMLODIPINE BESYLATE 227 212 3 6
FUROSEMIDE 209 179 4 7
OMEPRAZOLE 189 173 5 2
HYDROCODONE-ACETAMINOPHEN 167 159 S3 6 1
SIMVASTATIN 155 150 7 3
LISINOPRIL 154 150 8 5
SERTRALINE HCL 152 152 9 26
WARFARIN SODIUM 140 102 10 22
PANTOPRAZOLE SODIUM 138 122 11 28
FAMOTIDINE 129 119 12 88
CILOSTAZOL 121 110 13 227
METOPROLOL TARTRATE 109 91 14 19
FLUOXETINE HCL 102 93 15 51
METFORMIN HCL 94 89 16 8
CITALOPRAM HBR 93 88 17 17
ATENOLOL 92 88 18 24
GABAPENTIN 92 63 18 11
MIRTAZAPINE 87 86 20 56
QUETIAPINE FUMARATE 85 85 21 75
TRAZODONE HCL 79 57 22 29
DONEPEZIL HCL 73 72 23 32
PRAVASTATIN SODIUM 72 64 24 12
DIGOXIN 68 68 25 52
NAMENDA 68 68 25 43
PREDNISONE 68 57 25 42
ESCITALOPRAM OXALATE 62 51 28 60
ATORVASTATIN CALCIUM 61 57 29 18
PAROXETINE HCL 59 48 30 63
HYDROCHLOROTHIAZIDE 58 57 31 9
LOSARTAN POTASSIUM 55 47 32 25
ZOLPIDEM TARTRATE 54 51 33 16
TRAMADOL HCL 50 45 34 13
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Dec. 7, 2009.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.